CD274 and non-small cell lung carcinoma: The phase II CITYSCAPE study evaluated the use of the anti-LAG3 antibody, tiragolumab in combination with anti-PDL1 antibody, atezolizumab, as compared to the use of a placebo plus atezolizumab, as a first-line treatment for patients with PD-L1-positive advanced NSCLC.